From reporting challenges to data integration and data silos with clinical data management, to the continuing search for greater automation,…
Learn MoreAs different regulatory authorities have different timelines for adoption of these standards, E2B(R2) E2B(R3) will have to coexist. But having to operate two solutions creates huge complexities, unless you find a solution compliant with both. ArisGlobal LifeSphere Safety MultiVigilance is the only drug safety database solution provider thus far to provide full compliance to E2B R2 and E2B R3 standards for both import and export.
Learn MoreArtificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world…
Learn MoreSilos have long plagued the life sciences industry, and nowhere is this more notable than with how information and data…
Learn MoreToday’s Medical Information (MI) and Medical Affairs professionals are juggling multiple challenges: they must adapt to decentralization, outsourcing and globalization…
Learn MoreSafety departments at Marketing Authorization Holders & Regulatory Authorities are under pressure from all sides. They must constantly stay on…
Learn MoreRising Expectations from Regulatory Affairs Executives As we all know from experience, not all cloud solutions are the same and…
Learn MoreArtificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world as we know it. While there’s a lot of talk about how AI will affect jobs, where it will have the most powerful impact is on the quality of work and the speed at which manual tasks can be accomplished.
Learn MoreThis is the last in the ArisGlobal three-part blog series on Regulatory Affairs transformation. Digitization is sweeping the life sciences industry, disrupting traditional working practices and opening doors to better ways of collaborating, tracking and sharing documents and data, and gaining clear oversight into the product supply chain.
Learn MoreThe life sciences industry is confronting a wave of transformational change, brought about by multiple factors, including the growth of new clinical trial markets, a rapid rise in drug development innovation, reimbursement challenges, heightened regulatory requirements and a demand for evidence-based medicine, among many others. These drivers and the resultant changes are having a profound effect on regulatory affairs.
Learn More